Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Challenges and opportunities in spinal muscular atrophy therapeutics
Crystal Jing Jing Yeo, Eduardo F. Tizzano, Basil T. Darras
The Lancet Neurology (2024) Vol. 23, Iss. 2, pp. 205-218
Closed Access | Times Cited: 21

Showing 21 citing articles:

Advanced Delivery Systems for Gene Editing: A Comprehensive Review from the GenE-HumDi COST Action Working group
Alessia Cavazza, Francisco J Molina-Estévez, Álvaro Plaza Reyes, et al.
Molecular Therapy — Nucleic Acids (2025) Vol. 36, Iss. 1, pp. 102457-102457
Open Access | Times Cited: 2
Breaking genetic shackles: The advance of base editing in genetic disorder treatment
Fang Xu, Caiyan Zheng, Weihui Xu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 10
Deciphering spinal muscular atrophy: the need for more research
Michelle A. Farrar, Didu Sanduni Kariyawasam
The Lancet Neurology (2024) Vol. 23, Iss. 2, pp. 134-136
Closed Access | Times Cited: 4
Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study
Thomas O. Crawford, John Day, Darryl C. De Vivo, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 4
Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database
Wenwen Zhang, Yizhen Yin, Dan Yang, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
An exploratory qualitative assessment of patient and clinician perspectives on patient-reported outcome measures and disease-modifying therapies in adults with spinal muscular atrophy
Jeremy Slayter, Lauren Casey, Shane McCullum, et al.
Journal of Rehabilitation Medicine (2025) Vol. 57, pp. jrm41254-jrm41254
Open Access
Clinical relevance of zebrafish for gene variants testing. Proof-of-principle with SMN1/SMA.
Brett W. Stringer, Yougang Zhang, Afsaneh Taghipour Sheshdeh, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Trend in parameters of motor nerve conduction against the background of gene therapy in early age patients with spinal muscular atrophy
Daria A. Fisenko, А. Л. Куренков, Л. М. Кузенкова, et al.
L O Badalyan Neurological Journal (2025) Vol. 5, Iss. 4, pp. 192-200
Closed Access
La voz en la atrofia muscular espinal. Una revisión no sistemática
Celia Alba de la Torre
Revista de Logopedia Foniatría y Audiología (2025) Vol. 45, Iss. 1, pp. 100513-100513
Closed Access
Treating neuromuscular diseases: unveiling gene therapy breakthroughs and pioneering future applications
Yu‐Fu Wu, Jun‐An Chen, Yuh‐Jyh Jong
Journal of Biomedical Science (2025) Vol. 32, Iss. 1
Open Access
Stem cell therapy: A promising therapeutic approach for skeletal muscle atrophy
Yingjie Wang, Zehao Chen, Yuntian Shen, et al.
World Journal of Stem Cells (2025) Vol. 17, Iss. 2
Closed Access
Global, Regional, and National Burdens of Motor Neuron Disease 1990-2021: Systematic Analysis from GBD 2021
Weifang Tong, Shuai Qiu, Lingjing Jin, et al.
(2025)
Closed Access
Detection of Pathogenic Intronic Variants for COL4A5 Gene in X‐Linked Alport Syndrome: Developing a Novel Methodology
Yixiao Li, Rujin Tian, 裕之 目黒, et al.
Human Mutation (2025) Vol. 2025, Iss. 1
Open Access
The efficacy of gene therapy with onasemnogene abeparvovec in spinal muscular atrophy in young patients
Daria A. Fisenko, А. Л. Куренков, Л. М. Кузенкова, et al.
L O Badalyan Neurological Journal (2025) Vol. 6, Iss. 1, pp. 13-25
Closed Access
SMA Community Priorities for Future Drug Therapies: Cross-Sectional Survey Findings Representing 410 Adults with SMA
Ilse Peterson, Ramaa Chitale, Mary Ann Curry, et al.
Neurology and Therapy (2025)
Open Access
Patient-specific responses to SMN2 splice-modifying treatments in spinal muscular atrophy fibroblasts
Ilaria Signoria, Maria M Zwartkruis, Lotte Geerlofs, et al.
Molecular Therapy — Methods & Clinical Development (2024) Vol. 32, Iss. 4, pp. 101379-101379
Open Access | Times Cited: 1
Analysis of blood concentrations and clinical application of risdiplam in patients with spinal muscular atrophy using ultra‐high performance liquid chromatography–tandem mass spectrometry
Xian Wu, Zhiyan Lin, Yan Liu, et al.
Biomedical Chromatography (2024) Vol. 38, Iss. 10
Closed Access
Macrostructural Brain Abnormalities in Spinal Muscular Atrophy
Emilie Groulx-Boivin, Andrea Oliveira-Carneiro, Helen L. Carlson, et al.
Neurology Genetics (2024) Vol. 10, Iss. 5
Open Access
A Review of Neurogenetics in Fetal and Neonatal Clinical Medicine
Amitha Ananth, Michael A. Lopez
Seminars in Fetal and Neonatal Medicine (2024), pp. 101550-101550
Closed Access
Recombinant SMN protein synergizes with spinal muscular atrophy therapy to counteract pathological motor neuron phenotypes
Liliana Brambilla, Chiara F. Valori, Giulia Guidotti, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access
Patient-specific responses toSMN2splice-modifying treatments in spinal muscular atrophy fibroblasts
Ilaria Signoria, Maria M Zwartkruis, Lotte Geerlofs, et al.
(2024)
Open Access
Page 1

Scroll to top